- The field of ATMPs is evolving at a rapid pace while industrialization challenges are limiting access to these potentially curative treatments
- Managing complex supply chains will make the difference
- Digital solutions and innovating in key areas to reduce cost of manufacture are major enablers to drive access
Global Head, Cell and Gene Therapy, Genentech/Roche
Ralf Altenburger joined the Technical Operations Leadership Team at Roche/Genentech in July 2015 as Head of Pharma Technical Regulatory. Additionally, in Oct. 2021 he assumed the role of Global Head Cell and Gene Therapy. Ralf has more than 20 years of experience in the pharmaceutical industry and joined Roche in 2009 leading global functions in Technical Development. Prior to joining Roche, Ralf held roles of increasing responsibility in technical R&D at Merck KGaA and Novartis. He has a PhD in pharmaceutical technology from the Philipp University Marburg, Germany.